Drug intelligence / Profile preview

AEX-01

Development stage: Unknown
Lead developer: Aethox Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

AEX-01 is a first-in-class, orally bioavailable small-molecule therapeutic developed by Aethox Therapeutics, a spin-out from King's College London. It is designed to target and inhibit the tumour-associated macrophage (TAM) pathway, which typically mediates immune suppression and shields solid tumours from standard-of-care treatments. By blocking macrophage-mediated tumour protection and enhancing T-cell recruitment, AEX-01 aims to re-sensitize treatment-resistant cancers and improve the efficacy of chemotherapy. The drug is currently in preclinical development, with preparations underway for a first-in-human Phase 1 clinical trial in patients with solid tumours.

Other names: AEX-01AEX01AEX 01

Targets

HMOX1 (Heme oxygenase 1)

Beyond the preview

Go deeper on AEX-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AEX-01.

Explore the full profile